Synthetic RNA-Based Immunomodulatory Gene Circuits for Cancer Immunotherapy

Area of Science:

• Biotechnology
• Immunology
• Synthetic Biology

Background:

• Cancer immunotherapy faces challenges including rare tumor antigens, immune suppression, and systemic toxicity.
• Current immunotherapies require specific tumor antigens and can cause off-target effects.

Purpose of the Study:

• To develop a proof-of-concept immunomodulatory gene circuit for tumor-specific immunostimulation.
• To overcome limitations of current cancer immunotherapies by enhancing specificity and reducing toxicity.

Main Methods:

• Designed synthetic cancer-specific promoters and an RNA-based AND gate for combinatorial control.
• Engineered gene circuits to express an immunogenic protein, cytokine, chemokine, and checkpoint inhibitor antibody.
• Evaluated circuit efficacy in vitro for cancer cell killing and in vivo for tumor reduction.

Main Results:

• Demonstrated selective T cell-mediated killing of cancer cells, sparing normal cells in vitro.
• Achieved significant tumor reduction and prolonged mouse survival in vivo via lentiviral gene circuit delivery.
• Validated the combinatorial output of the AND gate for precise immune response activation.

Conclusions:

• The developed gene circuit platform shows potential for targeted cancer immunotherapy.
• This approach offers a strategy to overcome key limitations in current cancer treatment.
• The platform is adaptable for various immunomodulators, cancer types, and other diseases requiring immunological programming.